Correlation of radiotherapeutic parameters and treatment related morbidity—analysis of RTOG study 77-06

Pilepich, Miljenko V.; Asbell, Sucha O.; Krall, John M.; Baerwald, W.Hans; Sause, William T.; Rubin, Philip; Emami, B.; Pidcock, G.M.

doi:10.1016/0360-3016(87)90038-1

Cited by 118 publications

(26 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Data on urinary and intestinal side effects presented during the 1980's indicated a quite high percentage of minor problems from the intestine (blood, mucus) and from the urinary tract (urgency, leakage (8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)). This was also shown recently with a self-assessment questionnaire (19).…”

mentioning

confidence: 99%

Daily-Diary Evaluated Side-Effects of Conformal versus Conventional Prostatic Cancer Radiotherapy Technique

et al. 1997

View full text Add to dashboard Cite

mentioning

confidence: 99%

Daily-Diary Evaluated Side-Effects of Conformal versus Conventional Prostatic Cancer Radiotherapy Technique

et al. 1997

View full text Add to dashboard Cite

“…These trials established 70 Gy as the maximal tolerable dose prior to the advent of conformal planning techniques [Pilepich et al 1987a[Pilepich et al , 1987b Toxicity of three-dimensional conformal radiotherapy RTOG 9406 evaluated the development of grade 3 or greater GI or GU toxicity in five dose levels from 68.4 to 79.2 Gy delivered via a 3DCRT technique. Group 1 patients had no elective seminal vesicle irradiation.…”

Section: Toxicity Of Conventional Two-dimensional Planningmentioning

confidence: 99%

Radiation treatment for patients with intermediate-risk prostate cancer

Greene

Mayadev

Valicenti

2012

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Around 70% of men presenting with prostate cancer will have organ-confined disease, with the majority presenting with low-or intermediate-risk prostate cancer. This article reviews the evidence supporting the current standard of care in radiation oncology for the evaluation and management of men with intermediate-risk prostate cancer. Dose escalation, hormonal therapy, combined modality therapy, and modern techniques for the delivery of radiation therapy are reviewed.

show abstract

“…Although the authors recognize that these incidence values are approximate and somewhat arbitrary, the model that has been developed is far less dependent on the incidence of side effects than on the detriment to quality of life that results from these side effects. The model included complications due to hormones but not complications due to radiotherapy, [37][38][39] because the goal was to determine the added benefit/detriment associated with hormone therapy, and not with the local modality; it is presumed that the complications associated with the local modality would affect both groups similarly. Thus, in Equation 2 above, for shortterm hormone use, H 1 ϭ 0.20 and H 2 ϭ 0.0.…”

Section: Adjustment For Side Effects and Relative Importance Of Survimentioning

confidence: 99%

Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma

Jani

Kao

Hellman

2003

Cancer

View full text Add to dashboard Cite

BACKGROUNDHormone therapy commonly is used to treat metastatic, locally advanced, and localized prostate carcinoma. The objective of the current investigation was to determine, using the number‐needed‐to‐treat (NNT) method, the effect of using hormone therapy to treat locally advanced disease, with consideration given to both the complications and the known advantages associated with hormone therapy.METHODSA literature review was performed to determine 1) the absolute benefit, based on available clinical endpoints, associated with the addition of hormone therapy to external beam radiotherapy for locally advanced prostate carcinoma; 2) the incidence of side effects of short‐term and long‐term hormone therapy; and 3) the stepwise progression from biochemical failure to death. A model was constructed to estimate the complication/utility‐adjusted survival detriment resulting from the side effects of short‐term (≤ 6 months) and long‐term (> 6 months) hormone therapy, and the absolute/unadjusted and complication‐adjusted NNTs for the addition of short‐term and long‐term hormone therapy were computed. In all cases, the magnitudes and signs of the NNTs obtained were used to gauge the effect of hormone therapy.RESULTSThe unadjusted NNTs were positive and in most cases had relatively small magnitudes (the greater the NNT, the smaller the benefit) for both short‐term and long‐term hormone therapy; these results were expected, and they suggested that there is a strong benefit associated with the use of hormones adjuvant to radiotherapy for locally advanced disease. Adjusted NNTs remained positive and had relatively small magnitudes even after the introduction into the analysis of complications of short‐term and long‐term hormone therapy. This finding, although weak with respect to the effect of short‐term hormone therapy on cause‐specific survival, remained robust over the range of values for utility impairment expected from short‐term and long‐term hormone therapy.CONCLUSIONSThe benefits of short‐term and long‐term hormone therapy for locally advanced prostate carcinoma appear to be significant and to outweigh the associated side effects. Long‐term therapy appears to be better than short‐term therapy in terms of virtually all endpoints studied, even when the increased incidence of side effects is considered. The current investigation was successful in the use of the complication‐adjusted NNT method for oncologic and radiotherapeutic scenarios in which the results of randomized trials could be summarized, adjusted for treatment toxicity, and individualized to a given patient. Cancer 2003. © 2003 American Cancer Society.

show abstract

Correlation of radiotherapeutic parameters and treatment related morbidity—analysis of RTOG study 77-06

Cited by 118 publications

References 4 publications

Daily-Diary Evaluated Side-Effects of Conformal versus Conventional Prostatic Cancer Radiotherapy Technique

Daily-Diary Evaluated Side-Effects of Conformal versus Conventional Prostatic Cancer Radiotherapy Technique

Radiation treatment for patients with intermediate-risk prostate cancer

Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma

Contact Info

Product

Resources

About